Neurohormonal Hypothesis in Heart Failure
暂无分享,去创建一个
[1] E. Braunwald,et al. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. , 1962, The New England journal of medicine.
[2] S. Satoh,et al. Effects of renal nerve stimulation, norepinephrine and angiotensin II on renal blood flow in relation to release of PG-like substances in anesthetized dogs. , 1981, Archives internationales de pharmacodynamie et de therapie.
[3] A. D. de Bold,et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.
[4] N. Hollenberg,et al. Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.
[5] H. Brunner,et al. The Renin-Angiotensin-Aldosterone System in Congestive Heart Failure , 1983 .
[6] J. Cohn,et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.
[7] J. Cohn,et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.
[8] M. Packer,et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.
[9] P. Poole‐Wilson,et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.
[10] P A Poole-Wilson,et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. , 1989, Circulation.
[11] G. Schreiner,et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Pfeffer,et al. Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.
[13] H. Itoh,et al. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. , 1990, The Journal of clinical investigation.
[14] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[15] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[16] R. Schrier,et al. Pathogenesis of ascites formation : mechanism of impaired aldosterone escape in cirrhosis , 1991 .
[17] J. S. Janicki,et al. Cardiac myocyte necrosis induced by angiotensin II. , 1991, Circulation research.
[18] G Olivetti,et al. Cellular basis of ventricular remodeling after myocardial infarction. , 1991, The American journal of cardiology.
[19] P. Poole‐Wilson,et al. Plasma CGRP-like immunoreactivity in treated and untreated congestive heart failure , 1991, The Lancet.
[20] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[21] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[22] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[23] M. Packer. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.
[24] M. Packer,et al. Pathophysiology of chronic heart failure , 1992, The Lancet.
[25] F. Pagani,et al. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. , 1992, The Journal of clinical investigation.
[26] V. Dzau. Tissue renin-angiotensin system in myocardial hypertrophy and failure. , 1993, Archives of internal medicine.
[27] L. Vaca,et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. , 1993, The Journal of clinical investigation.
[28] M. Packer. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. , 1993, The American journal of cardiology.
[29] M. Kinoshita,et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.
[30] D. Mann,et al. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.
[31] M. Packer,et al. Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. , 1995, European heart journal.
[32] A. Quyyumi,et al. Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.
[33] A. Luchner,et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. , 1996, Kidney international.
[34] G. Maurer,et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.
[35] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[36] H. Drexler,et al. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. , 1997, Circulation.
[37] S. Anker,et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.
[38] P. Ponikowski,et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.
[39] L. Lind,et al. Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease , 1997, Journal of internal medicine.
[40] K. Wasserman,et al. Nitric oxide production during exercise in chronic heart failure. , 1997, American heart journal.
[41] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[42] B. Massie. 15 years of heart-failure trials: what have we learned? , 1998, The Lancet.
[43] F. Clubb,et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.
[44] C. Holt,et al. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. , 1998, Journal of molecular and cellular cardiology.
[45] M. Bristow. Why does the myocardium fail? Insights from basic science , 1998, The Lancet.
[46] R. Ferrari,et al. The neuroendocrine and sympathetic nervous system in congestive heart failure. , 1998, European heart journal.
[47] B. Lorell,et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. , 1999, Circulation.
[48] I. Anand. Neurohormonal modulation in chronic heart failure , 1999 .
[49] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.
[50] G. Schuler,et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. , 1999, Journal of the American College of Cardiology.
[51] D. Mann,et al. Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.
[52] G. Schuler,et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. , 1999, Journal of the American College of Cardiology.
[53] M K Davies,et al. ABC of heart failure. Pathophysiology. , 2000, BMJ.
[54] S. Anker,et al. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. , 2000, International journal of cardiology.
[55] E. Braunwald. Congestive heart failure: a half century perspective , 2001 .
[56] E. Braunwald. The Denolin lecture. Congestive heart failure: a half century perspective. , 2001, European heart journal.
[57] F. Boomsma,et al. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. , 2001, Cardiovascular research.
[58] S. Adamopoulos,et al. Effects of Growth Hormone Administration on Plasma Levels of Proinflammatory Cytokines and Soluble Apoptosis Mediators Fas/FasLigand in Patients with Dilated Cardiomyopathy , 2002 .
[59] Neurohormonal modulation in chronic heart failure , 2002 .
[60] J. N. Sharma,et al. Cardiovascular Properties of the Kallikrein-Kinin System , 2002, Current medical research and opinion.
[61] Richard Kamin,et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. , 2003, Journal of the American College of Cardiology.
[62] R. Sharma,et al. From tissue wasting to cachexia : changes in peripheral blood flow and skeletal musculature , 2004 .